WCIR: World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease Meeting [WCIR update, Source: Medpage Today)

Medicine 100 Comments

Biologics in diabetes

‘Doctors are excited about the prospects for a monoclonal antibody for type 2 diabetes. In vitro and murine studies of the compound, XMetA, have shown that it selectively targets an allosteric insulin receptor — offering all the glucoregulatory benefits, but none of the mitogenic effects, according to Yehuda Handelsman, MD president WCIR

Diabetics with OSA more at risk

Diabetes patients with obstructive sleep apnea may have more autonomic dysfunction and also may be at greater risk of hypoglycemia. Those with the sleep disorder who also had poor autonomic function had significantly more hypoglycemia than those with more normal function (P<0.05) as per Dr Jennifer Cheng, of Rosalind Franklin University of Medicine and Science in Chicago.

Renal hyperfiltration linked to stroke

Renal hyperfiltration is associated with a greater risk of stroke, especially in patients with the metabolic syndrome or type 2 diabetes. In a single-center study, 22% of patients with either condition who also had renal hyperfiltration had a stroke, Harold Pretorius, MD, PhD, of the Cincinnati Cognitive Collaborative in Ohio.

Hidden diabetes is common

About 25% of healthy people have either dysglycemia or undiagnosed type 2 diabetes as per Mona Boaz, PhD, of E. Wolfson Medical Center in Holon. More than 20% of people screened had impaired glucose tolerance, and that another 4% had [type 2] diabetes but they did not know it.

Weight loss the key for diabetics

In a survey, patients who reported weight loss had significantly greater improvements in several markers of quality of life, especially self-esteem and physical health, than those who gained weight (P<0.001),  Kathleen Fox, PhD, of Strategic Healthcare Solutions in Monkton, Md reported.

Monoclonal antibodies for diabetes

A monoclonal antibody selectively stimulated insulin signaling in vitro and improved fasting blood sugar in a mouse model, but its effects on humans remain to be seen. The fully human monoclonal antibody (XMetA) mimicked only the glucoregulatory action of insulin — not its growth factor pathway — and improved glycated hemoglobin (HbA1c) after six weeks of treatment in mice, according to John Corbin, PhD, of XOMA in Berkeley, Calif., a developer and manufacturer of therapeutic antibodies.